Phase II study of Pemetrexed + Carboplatin as first line therapy for nonsquamous non-small cell lung cancer with interstitial pneumonia
Phase 2
- Conditions
- no-small and non-squamous lung cancer with interstitial penumonia
- Registration Number
- JPRN-UMIN000011325
- Lead Sponsor
- Central Japan Lung Study Group (CJLSG)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 25
Inclusion Criteria
Not provided
Exclusion Criteria
1) Having uncontroled infection 2) Having a fever (more than 38 degrees (Celsius)) 3) Having past history of acute exacerbation of interstitial pneumonia 4) Progression of interstitial pneumonia on chest CT within 3 months 5) Over 21mg/day dose of predonisolone 6) Sarcoidosis and collagen vascular diseases 7) Having past history of drug-induced lung injury and radiation pnumonitis 8) Having severe complications 9) Active concomitant malignancy without evidence of recurrence within 5 years 10) Having an uncontrolable pleural effusion 11) Having allergy for pemetrexed or carboplatin 12) History of pregnancy or lactation 13) Decision of ineligibility by the attending physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method